Effects of the Androgen Antagonist Flutamide and the Serotonin Reuptake Inhibitor Citalopram in Bulimia Nervosa: A Placebo-Controlled Pilot Study

@article{Sundblad2005EffectsOT,
  title={Effects of the Androgen Antagonist Flutamide and the Serotonin Reuptake Inhibitor Citalopram in Bulimia Nervosa: A Placebo-Controlled Pilot Study},
  author={Charlotta Sundblad and Mika{\'e}l Land{\'e}n and Tomas Eriksson and Lars Bergman and Elias Eriksson},
  journal={Journal of Clinical Psychopharmacology},
  year={2005},
  volume={25},
  pages={85-88}
}
Abstract: Prompted by previous studies suggesting that bulimia nervosa in women may be associated with elevated serum levels of testosterone, we have evaluated the possible effect of androgen antagonism in this condition. To this end, women meeting the DSM-IV criteria of bulimia nervosa, purging type, were treated in a one-center study with the androgen receptor antagonist flutamide (n = 9), the serotonin reuptake inhibitor citalopram (n = 15), flutamide plus citalopram (n = 10), or placebo (n… 
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
TLDR
Until drugs are developed specifically for eating disorders, drugs developed for other conditions that are centrally acting and associated with beneficial psychotropic effects and/or reduced appetite or weight loss might be considered for repurposing in BN.
High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes.
  • A. Mech
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 2008
TLDR
In this clinic, ziprasidone monotherapy is successfully used to treat adult patients with bipolar I disorder who presented with mixed or depressive episodes and achieved full remission, presumably a reversal of medication-associated weight gain from the prior agents.
High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes
TLDR
In this clinic, ziprasidone monotherapy is successfully used to treat adult patients with bipolar I disorder who presented with mixed or depressive episodes and achieved full remission, presumably a reversal of medication-associated weight gain from the prior agents.
High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes
TLDR
In this clinic, ziprasidone monotherapy is successfully used to treat adult patients with bipolar I disorder who presented with mixed or depressive episodes and achieved full remission, presumably a reversal of medication-associated weight gain from the prior agents.
Medication for Binge Eating
TLDR
Until drugs are developed specifically for eating disorders with binge eating, drugs developed for other conditions that are centrally acting and associated with beneficial psychotropic effects or reduced appetite or weight loss might be considered for repurposing in BN and BED.
Endocrine and metabolic disorders in bulimic women and effects of antiandrogenic treatment
TLDR
An antiandrogenic OC treatment reduced meal-related hunger and gastric distention in women with bulimia nervosa and improved bulimic behavior in relation to reduced testosterone levels.
Sex Hormones and Appetite in Women: A Focus on Bulimia Nervosa
TLDR
The findings support that androgens could play a significant role in bulimic behavior and antiandrogenic treatment may develop into a new therapeutic approach in women with bulimia nervosa, especially in those bulimics with hyper androgenic symptoms.
Emerging drugs for eating disorder treatment
TLDR
Anorexia nervosa, bulimia nervosa and binge eating disorder (BN) comprise the currently recognised eating disorders; they share certain forms of comorbid psychopathology, particularly anxiety and mood disorders.
Bulimia nervosa treatment: a systematic review of randomized controlled trials.
TLDR
Evidence for medication or behavioral treatment for BN is strong, for self-help is weak; for harms related to medication is strong but either weak or nonexistent for other interventions; and evidence for differential outcome by sociodemographic factors is nonexistent.
...
...

References

SHOWING 1-8 OF 8 REFERENCES
Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide
TLDR
The effect of treatment with the testosterone antagonist flutamide in two women with severe bulimia is described and it is concluded that further investigations of the possible efficacy of androgen antagonism in eating disorders are warranted.
Aggressive Behavioral Characteristics and Endogenous Hormones in Women with Bulimia nervosa
TLDR
In BN, increased plasma levels of testosterone may play a role in the modulation of aggressiveness, and a significant positive correlation was found between testosterone plasma levels and aggressiveness in patients but not in controls.
Hormonal changes related to eating behavior in oligomenorrheic women.
TLDR
It is concluded that testosterone levels and variability of LH levels are related to eating behavior in patients referred for oligomenorrheic patients.
High levels of free testosterone in women with bulimia nervosa
Women with normal‐weight bulimia nervosa (n= 11) displayed significantly higher serum levels of free testosterone than age‐matched controls (6.0 ± 0.7 vs 3.9 ± 0.8 pmol/l; P= 0.03). The possible
Polycystic ovarian morphology and bulimia nervosa: a 9-year follow-up study.
Antiandrogenic treatment for obsessive-compulsive disorder.
  • T. Eriksson
  • Psychology
    The American journal of psychiatry
  • 2000
Antiandrogenic treatment of obsessive‐compulsive neurosis
Aggressive behavioural characteristics and endogenous hormones in women with bulimia nervosa. Neuropsychobiology
  • 2000